Arzoxifene: The evidence for its development in the management of breast cancer

Core Evidence

Volumn 2, Issue 4, 2008, Pages 251-258

  Jackson, Lee R ^a   Cheung, Kwok L ^a   Buzdar, Aman U ^b   Robertson, John F R ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Arzoxifene; Breast cancer; Selective estrogen receptor modulators (SERM)

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ARZOXIFENE; DROLOXIFENE; ESTROGEN RECEPTOR; FOLLITROPIN; GESTAGEN; IDOXIFENE; LUTEINIZING HORMONE; LY 335563; NORARZOXIFENE; OSTEOCALCIN; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TOREMIFENE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BACKACHE; BLADDER DISEASE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CATARACT; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; DYSPAREUNIA; DYSPNEA; ENDOMETRIUM CANCER; ESTROGEN ACTIVITY; EVIDENCE BASED MEDICINE; FOLLITROPIN BLOOD LEVEL; GYNECOLOGIC DISEASE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LEG CRAMP; LUNG EMBOLISM; LUTEINIZING HORMONE BLOOD LEVEL; MASTALGIA; MOTOR DYSFUNCTION; MUSCULOSKELETAL DISEASE; NAUSEA; NONHUMAN; OSTEOPOROSIS; OVARY CYST; PROTEIN EXPRESSION; PRURITUS; REVIEW; SIDE EFFECT; SKIN DISEASE; STOMATITIS; SWEATING; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; VAGINA BLEEDING; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; WEIGHT GAIN;

EID: 54749125018     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Baselga J, Llombart-Cussac A, Bellet M, et al. Randomized, double-blind, multicenter trial comparing two dosed of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Ann Oncol. 2003;14:1383-1390.
2. Beatson GW. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet. 1896;ii:104-7 & 162-165.
3. Black IJ, Goode RI. Uterine bioassay of tamoxifen, trioxifene and a new estrogen antagonist (LY117018) in rats and mice. Life Sci. 1980;26:1453-1458.
4. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G, Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology. 1988; 45:344-345.
5. Buzdar A, Hayes D, El-Khoudary A, et al. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/ PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002;73:161-175.
6. Buzdar A, O'Shaughnessy JA, Booser DJ, et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2003;21:1007-1014.
7. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat. 2001;65:125-134.
8. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003; 289: 3243-3253.
9. Clinical Trials,gov. Effects of arzoxifene on bone fractures and incidence of breast cancer. Available at: http://www.clincaltrials.gov/ ct/show/NCT0008801 0 (accessed August 20, 2007).
10. Clinical Trials.gov. Effects of arzoxifene on bone mass and the uterus. Available at: http://www.clinicaltrials.gov/ct/show/NCT0085956 (accessed August 20, 2007).
11. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189-2197.
12. Cuzick J, Forbes JF, Sestalk I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272-282.
13. Dardes RC, Bentrem D, O'Regan RM, Schafer JM, Jordan VC. Effects of the new selective estrogen receptor modulator LY353381.HCI (Arzoxifene) on human endometrial cancer growth in athymic mice. Clin Cancer Res. 2001;7:4149-4155.
14. Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar A. Phase III, double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007;25:4967-4973.
15. Detre S, Fiddler S, Satter J, A'Hern R, Dowsett M, Johnston SR: Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. Cancer Res. 2003;63:6516-6522.
16. Early breast cancer trialists' collaborative group. Ovarian ablation in early breast cancer: overview of the randomized trials. Lancet. 1996;348: 1189-1196,
17. Early breast cancer trialists' collaborative group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451-1467.
18. Early breast cancer trialists' collaborative group (EBCTGG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-1717.
19. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282:637-645.
20. Fabian CJ, Kimler BF, Anderson J, et al. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective receptor modulator. Clin Cancer Res. 2004; 10:5403-5417.
21. Fabian CJ, Kimler BF, Anderson JR, et al. Phase II breast cancer chemoprevention trial of the third generation selective estrogen receptor modulator arzoxifene. J Clin Oncol. 2006;24:1001.
22. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371-1388.
23. Freddie CT, Larsen SS, Bartholomaeussen M, Lykkesfeldt AE. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. Mol Cell Endocrinol. 2004;219:27-36.
24. Gottardis MM, Jordan VC. Development of tamaxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988; 48: 5183-5187.
25. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA. 1997;94:14105-14110.
26. Hayes DF, Robertson JFR. Overview and concepts of endocrine therapy. In: JFR Robertson, RI Nicholson, DF Hayes, editors. Endocrine therapy of breast cancer. London: Martin Dunitz; 2002, pp 3-10.
27. Johnston SRD. Acquired tamoxifen resistance in human breast cancer; potential mechanisms and clinical implications. Anticancer Drugs. 1997;8:911-930.
28. Johnston SR, Gorbunova V, Lichinitser M, et al. A multicentre double-blind randomised phase III trial of idoxifene versus tamoxifen as first-line endocrine therapy for metastatic breast cancer. Proc Am Soc Clin Oocol. 2001;20:29a. Abstract 113.
29. Kimler BF, Ursin G, Fabian CJ, et al. Effect of the third generation selective estrogen receptor modulator arzoxifene on marnmographic breast density. J Clin Oncol. 2006;24. Abstract 526.
30. Kostoglou-Athanassiou I, Ntalles K, Gogas J, et al. Sex hormones in post-menopausal women with breast cancer on tamoxifen. Horm Res.. 1997;47: 116-120.
31. Land SR, Wickerham DL, Costino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA. 2006;295:2742-2751.
32. Lønning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1995;52:491-496.
33. Ma YL, Bryant HU, Zeng Q, et al. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. J Bone Miner Res.. 2002; 17:2256-2264.
34. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natt Cancer inst. 2004;96:1751-1761.
35. McMeekin DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol. 2003;90:64-69.
36. Münster PN, Buzdar A, Dhingra K, et al. Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCI, in metastatic breast cancer. J Clinc Oncol. 2001;19:2002-2009.
37. Münster PN. Arzoxifene: the development and clinical outcome of an ideal SERM. Expert Opin Investig Drugs. 2006;15:317-326.
38. Office for National Statistics, Cancer Statistics registrations: Registrations of cancer diagnosed in 2004, England. Series MB1 no.35, 2007 London.
39. Osborne CK, Fuqua SAW, Mechanisms of tarnoxifen resistance. Breast Cancer Res Treat. 1994;32:49-55.
40. Osipo C, Gajdos C, Cheng D, Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. J Steroid Biochem Mol Biol. 2005;93: 249-256,
41. Palkowitz AD, Glasebrook AL, Thrasher KJ, et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1 -piperidinyl)ethoxylphenoxyj-2-(4-hydroxyphenyl)lbenzo [blthiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem. 1997;40:1407-1416.
42. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283-290.
43. Pyrhönen S, Ellmén J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1999;56:133-143.
44. Ries LAG, Melbert D, Krapcho M, Mariotto A, et al, editors. SEER Cancer Statistics Review, 1975-2004, National Cancer Institute. Bethesda, MD, based on November 2006 SEER data submission posted to the SEER web site, 2007. Available at: http://seer.cancer.gov/csr/1975_~2004/ (accessed March 18, 2008).
45. Sato M, Turner CH, Wang T, Adrian MD, Rowley E, Bryant HU. LY353381.HCI: a novel raloxifene analog with improved SERM potency and efficacy in vivo. J Pharmacol Exp Ther. 1998;287:1-7.
46. Schafer JM, Lee ES, Dardes RC, et al. Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer. Clin Cancer Res. 2001;7:2505-2512.
47. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMS. Science. 2002;295:2465-2468.
48. Suh N, Glasebrook Al, Palkowitz AD, et al. Arzoxifene. A new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer Res. 2001;61:8412-8415.
49. Vogel VG, Costantino JR Wickerham DL, et al. National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxitene (STAR) P-2 Trial. JAMA. 2006;295:2727-2741.